# A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

> **NCT02571829** · PHASE2 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 30 (estimated)

## Conditions studied

- Liposarcoma
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** ribociclib

## Key facts

- **NCT ID:** NCT02571829
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2017-08
- **Final completion:** 2017-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571829, "A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02571829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*